Soretolide: Laboratoires Biocodex

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.

Original languageEnglish
Pages (from-to)824-827
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number6
Publication statusPublished - 2001

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this